Foundayo Gains Approval: UK’s New Hope in Oral Weight Loss and Diabetes Treatment
The UK has become the first country in Europe to authorize Eli Lilly‘s pill, Foundayo, for weight management and type 2 diabetes. While not yet availableate prescription, presenting a new competitor to Novo Nordisk’s Wegovy in the oral treatment market
Devdiscourse News Desk|Updated: 11-08-2026 01:36 IST | Created: 11-08-2026 01:36 IST
- Country:
- United Kingdom
Analyzing article…
In a significant development for weight management and diabetes treatment, Britain’s medicines regulator has authorized Eli Lilly’s new pill, Foundayo. This move makes the UK the first European country to approve the tablet for both conditions
Despite its approval, Foundayo is not currently accessible through the NHS. A representative from Lilly confirmed that private prescriptions will start later this month, with costs lower than that of their injectable counterpart, Mounjaro, which is priced at £330 for a month’s supply
While Foundayo is under review in the European Union, its rival, Novo Nordisk’s Wegovy pill, is also vying for market dominance. The emerging trend of GLP-1 oral pills is expanding a market traditionally dominated by injectables
ALSO READ
Breaking New Ground: Foundayo Pill Revolutionizes Weight Management and Diabetes Care in Europe
UK First to Approve Eli Lilly’s Weight Loss Pill Foundayo
UK Greenlights First Ever GLP-1 Weight Loss Pill
